GAMMACAN CONSUMMATES INITIAL INVESTMENT OF $500,000 WITH AN OPTION OF UP TO $2.5 MILLION FINANCING

A A

GammaCan International (OTC BB: GCAN), a developer of immunotherapies for cancer and other diseases, consummated an initial investment of $500,000.00, by Sal. Oppenheim jr. & Cie. (Switzerland) Ltd., with an option for them to invest an additional $2 million in accordance with a private placement which closed on October 31, 2005. Details of the transaction have been publicly disclosed in a Form 8-K filed with the Securities and Exchange Commission on November 3, 2005.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1107073XSL_NEWSML_TO_NEWSML_WEB.xml)